Tokuyama (4043) Q4 2026 earnings summary

Executive summary

• Net sales rose 1.9% year-over-year to ¥349.4 billion, driven by semiconductor-related product growth and the consolidation of the Tokuyama Life Science Group.

• Operating profit increased 24% to ¥37.0 billion, supported by improved manufacturing costs and higher sales volumes in key segments.

• Profit attributable to owners of parent declined 5.1% to ¥22.2 billion due to higher income taxes and extraordinary losses.

• Comprehensive income surged 57.6% to ¥30,355 million.

Financial highlights

• Ordinary profit increased 29.1% year-over-year to ¥38.2 billion.

• Cost of sales decreased 4.4% to ¥224,530 million, reflecting manufacturing efficiencies.

• SG&A expenses increased 12.5% to ¥87,928 million, mainly from TLS Group consolidation.

• Basic earnings per share decreased to ¥308.64 from ¥325.08.

• Total assets rose to ¥557.4 billion, up ¥81.2 billion from the prior year.

Outlook and guidance

• No consolidated performance or dividend forecast for FY2026 due to high uncertainty from geopolitical risks, raw material procurement, and supply chain disruptions.

• The medium-term management plan will be announced on May 29, 2026.